New Approach to Chronic Back Pain Treatment: A Case Control Study
Controlled trialHumansWith alpha-lipoic acid and myrrh, with CT-guided periradicular oxygen-ozone injections
This study tested palmitoylethanolamide together with alpha-lipoic acid and myrrh, with CT-guided periradicular oxygen-ozone injections. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Controlled trial
- Subjects
- 246 patients with chronic low back pain (Group A) and 176 patients treated with periradicular steroid injections (Group B)
- Dose used in the study
- 800 mg/day alpha-lipoic acid, 600 mg/day palmitoylethanolamide and 200 mg/day myrrh by mouth, with oxygen-ozone periradicular injections under CT guidance
- Duration
- Follow-up at one week, three months and six months
- What was measured
- Clinical outcome by a modified McNab method at one week, three months and six months.
What the authors reported
In Group A, complete remission of pain was recorded in 206 patients (83.7%) at one week, 191 (77.6%) at three months and 178 (72.3%) at six months. In Group B (steroid injections), excellent results were recorded in 103 (80.5%) at one week, 85 (66.4%) at three months and 72 (56.2%) at six months; poor results rose to 32 (25%) at six months.
Limits of this study
Not randomised; the two groups had different injection treatments, so the oral supplement's own contribution cannot be separated. No blinding or statistics are reported in the abstract. The authors declare no conflict of interest.
Source
PubMed 36672581 · doi:10.3390/biomedicines11010073
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.